Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Almonty Announces Intention to Relocate to the United States (click to learn more) Benton Intersects 22.0 m Grading 7.47% Copper Including 8.0 m Grading 11.93% Copper (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GeneDx Holdings Corp WGS

Financial Services Healthcare Medical Care
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing... see more

Recent & Breaking News (NDAQ:WGS)

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 3 days ago

GeneDx Announces Preliminary 2024 Financial Results

Business Wire 7 days ago

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

Business Wire 11 days ago

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

Business Wire 12 days ago

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

Business Wire January 2, 2025

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire December 16, 2024

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

Business Wire December 5, 2024

GeneDx to Participate in Upcoming Investor Conference

Business Wire November 22, 2024

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

Business Wire November 19, 2024

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Business Wire November 18, 2024

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

Business Wire November 7, 2024

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Business Wire November 4, 2024

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Business Wire October 29, 2024

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Business Wire October 24, 2024

GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns

Business Wire October 8, 2024

GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Business Wire October 3, 2024

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 27, 2024

GeneDx to Participate in Fall Investor Conferences

Business Wire August 12, 2024

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 9, 2024

GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire July 30, 2024